Strategic Asset Move BioTrace sold assets to Merit Medical Systems in 2022 and integrated the Tempo Lead into Merit's portfolio, signaling a strategic pivot that may open opportunities to re-engage with Merit or target complementary product gaps resulting from this transition.

Targeted Account Fit As a venture-backed, small team focused on temporary pacing, BioTrace may be receptive to partnerships or OEM collaborations that leverage larger manufacturers’ distribution networks, potentially expanding reach in interventional and diagnostic markets.

Expansion Potential With a revenue range in the low to mid millions and a focus on hospital cost reduction, there is room to position cost-effective pacing solutions to health systems seeking efficiency gains and to pursue larger hospital networks aligned with portfolio changes after the Merit acquisition.

Strategic Outreach Despite the asset sale, BioTrace remains a platform for innovative temporary pacing technologies; approaching them with value propositions around speed-to-market, regulatory support, and integration with existing hospital workflows could unlock pilot opportunities.

Competitive Landscape Parked alongside large medical device players (Cook Medical, Abbott, AngioDynamics, Medtronic, Boston Scientific), BioTrace represents a niche opportunity to collaborate on smaller-scale deployments or co-development projects that leverage established distributor channels and hospital procurement paths.